Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22616865 | 1.00 | MEN1 (0.60) | MEN1KMT2AATMLMNAKDM4E | |
| SCHEMBL95469 | 1.00 | MEN1 (0.60) | MEN1KMT2AATMLMNAKDM4E | |
| SCHEMBL9656438 | 0.85 | LMNA (0.46) | MEN1KMT2AATMLMNAKDM4E | |
| SCHEMBL9656453 | 0.85 | LMNA (0.46) | MEN1KMT2AATMLMNAKDM4E | |
| SCHEMBL2121638 | 0.80 | LMNA (0.46) | MEN1KMT2AATMLMNAKDM4E | |
| SCHEMBL1944902 | 0.80 | LMNA (0.46) | MEN1KMT2AATMLMNAKDM4E | |
| SCHEMBL9460583 | 0.80 | LMNA (0.46) | MEN1KMT2AATMLMNAKDM4E | |
| SCHEMBL10996469 | 0.79 | LMNA (0.45) | MEN1KMT2AATMLMNAKDM4E | |
| SCHEMBL31303664 | 0.79 | ATM (0.53) | MEN1KMT2AATMLMNAALDH1A1 | |
| SCHEMBL10996466 | 0.79 | LMNA (0.45) | MEN1KMT2AATMLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115805042-A | Continuous flow reaction equipment suitable for suspended material under high temperature condition | 上海合全药业股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-112675920-B | Mono-chiral center catalyst, preparation thereof and method for catalytically synthesizing chiral alcohol compound and chiral alpha-allyl alcohol | 南方科技大学 | 2022-12-20 | — | — | CN | disclosed |
| CN-112675920-A | Mono-chiral center catalyst, preparation thereof and method for catalytically synthesizing chiral alcohol compound and chiral alpha-allyl alcohol | 南方科技大学 | 2021-04-20 | — | — | CN | disclosed |
| US-9486421-B2 | Treatment of lung cells with histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2016-11-08 | — | — | US | disclosed |
| CN-103007570-B | A kind of method prepared by integrated Chinese medicine material dehydration, extraction of essential oil and essential oil | LIU DONGBO (CN) | 2016-03-02 | — | — | CN | disclosed |
| US-8420698-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2013-04-16 | — | — | US | disclosed |
| CN-103007570-A | Integrated method for dehydrating traditional Chinese medicine materials, extracting essential oil and preparing essential oil | LIU DONGBO | 2013-04-03 | — | — | CN | disclosed |
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138225-B2 | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds | ERRANT GENE THERAPEUTICS, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20120035257-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2003099272-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETOEPOXIDE COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030125306-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | CIRCAGEN PHARMACEUTICAL, A MARYLAND CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| EP-0503884-B1 | Optically active diphenylphosphino-binaphtyl compounds and catalytic transition metal complexes thereof | TAKASAGO PERFUMERY CO LTD (JP) | 1995-07-26 | — | — | EP | disclosed |
| US-5231202-A | OPTICALLY ACTIVE TERTIARY PHOSPHINE COMPOUND AND TRANSITION METAL COMPLEX USING THE SAME AS LIGAND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1993-07-27 | — | — | US | disclosed |
| EP-0503884-A1 | Optically active diphenylphosphino-binaphtyl compounds and catalytic transition metal complexes thereof | Takasago International Corporation (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035257-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC11, HDAC9 | MEN1 1839/4885KMT2A 70/4885ATM 1535/4885 |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | ZFX, HDAC5, ZNF277 | MEN1 3991/4885KMT2A 179/4885ATM 1840/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | MEN1 1684/4885KMT2A 69/4885ATM 1453/4885 |
| US-20030125306-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | MEN1 1684/4885KMT2A 69/4885ATM 1453/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | MEN1 2334/4885KMT2A 77/4885ATM 1220/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | MEN1 1954/4885KMT2A 82/4885ATM 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.